CompletedNCT02695355
ERP Based Single-dose Predictions of Stimulants
Researchers studied Methylphenidate (MPH) to find out how it affected ADHD symptoms in children with ADHD.
Medication studyAges 8–17Norway
Understand this study
What did researchers investigate?
Researchers studied Methylphenidate (MPH) to find out how it affected ADHD symptoms in children with ADHD.
Who was this study for?
Listed age limits: 8 years to 17 years.
- Listed locations
- Fredrikstad, NorwaySee all locations and recruitment
- Activities
- Medication described in the protocol
- Compensation
- Payment and expense reimbursement have not been verified.
Study information
Study start dateOctober 2006
- Recruitment status
- Completed
- Enrollment listed in the registry
- 87
- Sponsor
- Ostfold Hospital Trust
- Sponsor type
- Hospital / academic medical center
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- Norway
- Age range
- From 8 Years to 17 Years
- Official registry ID
- NCT02695355
- Official title
Show the full official title
Pediatric Attention Deficit Hyperactivity Disorder: Predicting Clinical Response to Stimulant Medication From Single-dose Changes in Event Related Potentials
Recruitment & locations
CompletedFredrikstad
Questions about this study
What did researchers investigate?
Researchers studied Methylphenidate (MPH) to find out how it affected ADHD symptoms in children with ADHD.
Who is behind this study?
The study sponsor is Ostfold Hospital Trust, a hospital or academic medical center.
Did this study involve medication?
Yes. The study involved medication, including Methylphenidate (MPH).
Who was this study for?
Listed age limits: 8 years to 17 years.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meExplore related studies
Other studies that may be relevant based on condition, country, or study type.
CompletedEUCTR 2010-021533-31
A 40-week, randomized, double-blind, placebo-controlled, multicenter efficacy and safety study of Ritalin® LA in the treatment of adult patients with childhood-onset ADHD
Belgium, Denmark, Germany, + 2 others
CompletedNCT00447278
A Study Comparing the Effect of Atomoxetine Versus Other Standard Care Therapy on the Long Term Functioning in Attention-Deficit/Hyperactivity Disorder (ADHD) Children and Adolescents
France, United Kingdom, Belgium, + 6 others
CompletedNCT00714688
Effectiveness of Effectiveness and Safety of Prolonged Release OROS Methylphenidate in ADHD
France, United Kingdom, Switzerland, + 8 others